微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | 66.08% | 8.24% | 17% | 40/157 | 50.55% | 海创药业 | 99.82% | 行业排名> |
| 2025-12-31 | 56.48% | -7.94% | -4.65% | 59/157 | 50.61% | 海创药业 | 98.62% | 行业排名> |
| 2025-09-30 | 59.23% | -10.97% | 1.63% | 54/157 | -2.2% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 58.28% | -19.36% | -4.53% | 56/157 | 14.83% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 61.05% | -19.43% | -0.49% | 44/157 | 31.96% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 61.35% | -24.3% | -7.79% | 50/157 | 51.88% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 66.53% | -18.01% | -7.94% | 39/157 | 22.51% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 72.27% | -13.43% | -4.62% | 30/157 | 33.12% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 75.77% | -11.82% | -6.5% | 25/157 | 51.76% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 81.04% | -6.67% | -0.13% | 22/157 | 51.61% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 81.15% | -6.57% | -2.8% | 23/157 | 32.47% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 83.49% | -4.35% | -2.84% | 15/157 | 38.42% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 85.93% | -4.35% | -1.05% | 12/157 | 52.97% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 86.83% | 1.54% | -0.02% | 12/157 | 53.83% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 86.85% | 2.51% | -0.49% | 11/157 | 5.64% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 87.28% | 2.22% | -2.85% | 11/157 | 20.99% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 89.83% | 3.59% | 5.05% | 6/157 | 54.39% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 85.52% | 3.83% | 0.94% | 18/157 | 55.2% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 84.72% | 3.56% | -0.78% | 15/157 | 46.77% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 85.38% | 5.04% | -1.54% | 14/157 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 86.72% | 1.38% | 5.28% | 12/157 | 54.13% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 82.37% | 6.16% | 0.68% | 18/157 | -148.64% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 81.81% | 4.01% | 0.64% | 18/157 | 56.43% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 81.29% | 5.87% | -4.97% | 17/157 | 54.17% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 85.54% | 6.37% | 10.26% | 10/157 | 55.17% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 77.58% | 7.05% | -1.36% | 23/157 | -1242.15% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 78.65% | 12.54% | 2.44% | 14/157 | 55.23% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 76.78% | 19.62% | -4.52% | 19/157 | 55.21% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 80.42% | 30.74% | 10.96% | 12/157 | 51.07% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 72.48% | 24.99% | 3.7% | 29/157 | -211.97% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 69.89% | 25.22% | 8.89% | 23/157 | 54.14% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 64.19% | 12.71% | 4.35% | 32/157 | 53.53% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 61.51% | 2% | 6.08% | 37/157 | 54.16% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 57.98% | 11.34% | 3.88% | 47/157 | 52.55% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 55.82% | 2% | -1.99% | 35/157 | 49.09% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 56.95% | 2% | 9.34% | 33/157 | 47.91% | 贝达药业 | 95.81% | 行业排名> |
| 2016-12-31 | 52.08% | -2.54% | -2.54% | 44/157 | 48.46% | 退市金泰 | 95.93% | 行业排名> |